StockDrifts LogoStockDrifts

Foresite Capital Management V 13F Portfolio

Portfolio Manager
Foresite Capital Management V LLC
Performance
+21.06% (2026 Q2)
AUM (13F)
$362.20M
# of Holdings
9
Performance Rank
Allocation (Top 20)
96.31%
Latest filing
Q2 2026

Foresite Capital Management V LLC Holdings Map

Top 8 Foresite Capital Management V LLC Holdings

Top 10 holdings

StockCompany% Port.SharesValueActivityOwnershipAvg. CostDate
ALMS
ALUMIS INC.
45.81%5.90M$165.9M
+0.00%(+0)
2025-Q2: 5.78M shares2025-Q3: 5.78M shares2025-Q4: 5.78M shares2026-Q1: 5.90M shares2026-Q2: 5.90M shares
$13.22(+91.47%)
2026-06-30
CGON
CG Oncology, Inc.
21.17%1.08M$76.7M
+7.47%(+75.00K)
2025-Q2: 1.00M shares2025-Q3: 1.00M shares2025-Q4: 1.00M shares2026-Q1: 1.00M shares2026-Q2: 1.08M shares
$40.49(+86.70%)
2026-06-30
IRON
Disc Medicine, Inc.
7.55%374.1K$27.4M
+0.00%(+0)
2025-Q2: 299.1K shares2025-Q3: 299.1K shares2025-Q4: 299.1K shares2026-Q1: 374.1K shares2026-Q2: 374.1K shares
$44.83(+75.87%)
2026-06-30
HIMS
Hims & Hers Health, Inc.
7.07%738.2K$25.6M
+0.00%(+0)
2025-Q2: 273.2K shares2025-Q3: 273.2K shares2025-Q4: 273.2K shares2026-Q1: 738.2K shares2026-Q2: 738.2K shares
$19.74(+42.57%)
2026-06-30
PHVS
Pharvaris N.V.
6.34%664.1K$23.0M
+242.12%(+470.02K)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 194.1K shares2026-Q2: 664.1K shares
$30.08(+16.83%)
2026-06-30
EIKN
Eikon Therapeutics, Inc.
4.75%1.32M$17.2M
+0.00%(+0)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 1.32M shares2026-Q2: 1.32M shares
$10.58(+4.44%)
2026-06-30
LYEL
Lyell Immunopharma, Inc.
1.85%476.4K$6.7M
-0.15%(-692)
2025-Q2: 406.7K shares2025-Q3: 477.1K shares2025-Q4: 477.1K shares2026-Q1: 477.1K shares2026-Q2: 476.4K shares
$19.07(-26.85%)
2026-06-30
NRIX
Nurix Therapeutics, Inc.
1.77%265.0K$6.4M
+0.00%(+0)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 265.0K shares2026-Q2: 265.0K shares
$17.23(+56.95%)
2026-06-30

About Foresite Capital Management V LLC’s portfolio

Foresite Capital Management V LLC reports $362.20M in US-listed equity holdings across 9 positions in its most recent 13F filing. Its largest disclosed positions are ALMS (45.8%), CGON (21.2%) and IRON (7.5%). The top 20 holdings account for 96.31% of reported assets. Its disclosed equity book has returned +169.99% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.

Portfolio concentration

Portfolio concentration
ALMS — 47.6% ($165.94M)CGON — 22.0% ($76.67M)IRON — 7.8% ($27.36M)HIMS — 7.3% ($25.59M)PHVS — 6.6% ($22.97M)EIKN — 4.9% ($17.21M)LYEL — 1.9% ($6.69M)NRIX — 1.8% ($6.43M)
100%in top 8
  • ALMS47.6%
  • CGON22.0%
  • IRON7.8%
  • HIMS7.3%
  • PHVS6.6%
  • EIKN4.9%
  • LYEL1.9%
  • NRIX1.8%

Portfolio changes

What the fund actually did

Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.

Added to
2
PHVSPharvaris N.V.+242.1%
CGONCG Oncology, Inc.+7.5%
Trimmed
1
LYELLyell Immunopharma, Inc.-0.1%

Unlock alerts, watchlists & AI chat

Sign up free to track Foresite Capital Management V LLC, compare funds side by side, and get alerts the moment positions change.

Source filings

Holdings on this page are parsed from Foresite Capital Management V LLC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1792206). View Foresite Capital Management V LLC’s 13F filings on SEC

More 13F analyses

View all